Get the Stockscreener App
4.21
1.41%
-0.06
After Hours:
4.22
0.010
+0.24%
Fortress Biotech Inc stock is traded at $4.21, with a volume of 883.63K.
It is down -1.41% in the last 24 hours and up +48.76% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$4.27
Open:
$4.3
24h Volume:
883.63K
Relative Volume:
1.60
Market Cap:
$130.67M
Revenue:
$80.97M
Net Income/Loss:
$-78.31M
P/E Ratio:
-0.3798
EPS:
-11.0849
Net Cash Flow:
$-129.56M
1W Performance:
+17.60%
1M Performance:
+48.76%
6M Performance:
+123.94%
1Y Performance:
+86.28%
1-Day Range:
$4.015
$4.30
1-Week Range:
$3.59
$4.34
52-Week Range:
$1.325
$4.34
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
4.21 | 132.53M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Affects Rotational Strategy Timing - Stock Traders Daily
Signal Recap: Will Fortress Biotech Inc stock benefit from AI adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - moha.gov.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Fortress Biotech Inc stockEx-Dividend Date Alerts & High Yield Portfolio Growth - earlytimes.in
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 28% Price Jump - 富途牛牛
Can Fortress Biotech Inc. stock hit record highs again2025 Bull vs Bear & AI Forecast for Swing Trade Picks - DonanımHaber
Will Fortress Biotech Inc. stock benefit from AI adoptionMarket Growth Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Is Fortress Biotech Inc.(CNB0) stock resilient in recession scenarios2025 Market WrapUp & AI Powered Market Trend Analysis - Улправда
Fortress Biotech (NASDAQ: FBIO) registers 600,000 shares for Oaktree resale - Stock Titan
What momentum indicators show for Fortress Biotech Inc. stockJuly 2025 Big Picture & Weekly Setup with High ROI Potential - Улправда
Fortress Biotech amends credit agreement with Oaktree - MSN
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech’s CUTX-101 NDA resubmission accepted by FDA - MSN
Fortress Biotech (FBIO) files for 600K share offering by selling stockholders - StreetInsider
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Fortress Biotech (Nasdaq: FBIO) resale filing covers 600,000 shares for Oaktree - Stock Titan
Fortress Biotech Amends Credit Agreement with Oaktree - TipRanks
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (NASDAQ: FBIO) extends loan maturity and grants warrants - Stock Titan
Fortress Biotech, Inc. Enters into First Amendment to Credit Agreement - marketscreener.com
Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission - marketscreener.com
FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy - Investing.com Nigeria
Fortress Biotech Rises After FDA Accepts Application for Menkes Treatment - marketscreener.com
Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission - TipRanks
Fortress Biotech, Cyprium get FDA acceptance for CUTX-101 NDA resubmission - marketscreener.com
Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission - TradingView — Track All Markets
Fortress Biotech’s CUTX-101 NDA Resubmission Accepted by FDA - TipRanks
Fortress Biotech (FBIO) Resubmits Application for Menkes Disease Treatment - GuruFocus
Fortress Biotech Announces FDA Acceptance of CUTX-101 NDA Resubmission - TradingView — Track All Markets
[8-K] Fortress Biotech, Inc. Reports Material Event | FBIO SEC FilingForm 8-K - Stock Titan
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewswire
Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2025 Earnings Call Transcript - MSN
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewswire
(FBIOP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2025-12-08 06:59:10 - moha.gov.vn
FBIOP | Fortress Biotech, Inc. 9.375% Stock Data, Price & News - Quiver Quantitative
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Is Fortress Biotech Inc.(CNB0) stock undervalued historicallyWeekly Trading Summary & Pattern Based Trade Signal System - Newser
Fortress Biotech Inc (FBIO) looking to reclaim success with recent performance - setenews.com
Will Fortress Biotech Inc. stock gain from strong economyJuly 2025 Recap & Verified Swing Trading Watchlist - Newser
Why analysts remain bullish on Fortress Biotech Inc. stock2025 Top Decliners & Step-by-Step Swing Trade Plans - Newser
How Fortress Biotech Inc.(CNB0) stock reacts to monetary easingDollar Strength & Capital Efficiency Focused Ideas - Newser
Is Fortress Biotech Inc.(CNB0) stock a fit for income portfolios2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):